Literature DB >> 21259038

Exacerbation history is associated with medication and appointment adherence in MS.

Laura M Hancock1, Jared M Bruce, Sharon G Lynch.   

Abstract

Disease-modifying treatments are designed to prevent exacerbations in multiple sclerosis (MS). To date, few studies have examined the relationship between disease activity and treatment adherence in MS. The primary aim of this study was to examine the association between disease activity (e.g., annualized relapse rates), medication adherence, and appointment adherence in relapsing-remitting MS. Retrospective exacerbation and appointment data were collected and used to predict prospective medication adherence. Results indicated that patients with higher annualized relapse rates missed fewer doses of medication and were less likely to miss appointments. Conversely, patients with relatively stable disease were more likely to demonstrate poor medication adherence and poor appointment adherence. Patients who missed more appointments also missed more doses of their disease modifying medication. Future studies may wish to examine clinical methods designed to improve immunotherapy adherence among patients who are in relatively symptom-free stages of relapsing-remitting MS.

Entities:  

Mesh:

Year:  2011        PMID: 21259038     DOI: 10.1007/s10865-011-9316-x

Source DB:  PubMed          Journal:  J Behav Med        ISSN: 0160-7715


  52 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Adaptation of a motivational interviewing intervention to improve antidepressant adherence among Latinos.

Authors:  Alejandro Interian; Igda Martinez; Lisbeth Iglesias Rios; Jonathan Krejci; Peter J Guarnaccia
Journal:  Cultur Divers Ethnic Minor Psychol       Date:  2010-04

3.  Revised estimate of the prevalence of multiple sclerosis in the United States.

Authors:  D W Anderson; J H Ellenberg; C M Leventhal; S C Reingold; M Rodriguez; D H Silberberg
Journal:  Ann Neurol       Date:  1992-03       Impact factor: 10.422

Review 4.  Motivational interviewing for adherence problems in cystic fibrosis.

Authors:  Alistair J A Duff; Gary J Latchford
Journal:  Pediatr Pulmonol       Date:  2010-03

5.  Brief report: Predictors of optimal HIV appointment adherence in minority youth: a prospective study.

Authors:  Angulique Outlaw; Sylvie Naar-King; Monique Green-Jones; Kathryn Wright; Kathryn Condon; Lauren Sherry; Heather Janisse
Journal:  J Pediatr Psychol       Date:  2010-02-08

6.  Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program.

Authors:  Elizabeth A Walker; Mark Molitch; M Kaye Kramer; Steven Kahn; Yong Ma; Sharon Edelstein; Kellie Smith; Mariana Kiefer Johnson; Abbas Kitabchi; Jill Crandall
Journal:  Diabetes Care       Date:  2006-09       Impact factor: 19.112

7.  Family behavior, adaptation, and treatment adherence of pediatric nephrology patients.

Authors:  M C Davis; C M Tucker; R S Fennell
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

8.  Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Authors:  Francesco Patti
Journal:  Patient Prefer Adherence       Date:  2010-02-04       Impact factor: 2.711

9.  Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.

Authors:  Stephanie C Steinberg; Richard J Faris; Cyril F Chang; Andrew Chan; Mark A Tankersley
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

10.  Disease-modifying therapy in multiple sclerosis: update and clinical implications.

Authors:  Douglas S Goodin
Journal:  Neurology       Date:  2008-12-09       Impact factor: 9.910

View more
  5 in total

1.  Baseline predictors of DMT reinitiation among patients with multiple sclerosis following an MI-CBT intervention.

Authors:  Joanie Thelen; Amanda Bruce; Delwyn Catley; Sharon Lynch; Kathy Goggin; Andrea Bradley-Ewing; Morgan Glusman; Abigail Norouzinia; Lauren Strober; Jared Bruce
Journal:  J Behav Med       Date:  2017-11-09

2.  Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.

Authors:  Christian Bischoff; H Schreiber; A Bergmann
Journal:  J Neurol       Date:  2012-04-18       Impact factor: 4.849

3.  Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis.

Authors:  Aliza Ben-Zacharia; Meagan Adamson; Allison Boyd; Paula Hardeman; Jennifer Smrtka; Bryan Walker; Tracy Walker
Journal:  Int J MS Care       Date:  2018 Nov-Dec

Review 4.  The conundrum of iron in multiple sclerosis--time for an individualised approach.

Authors:  Susan J van Rensburg; Maritha J Kotze; Ronald van Toorn
Journal:  Metab Brain Dis       Date:  2012-03-17       Impact factor: 3.584

5.  Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study.

Authors:  Andrea Zimmer; Michael Coslovsky; Ivo Abraham; Bernhard F Décard
Journal:  Patient Prefer Adherence       Date:  2017-10-20       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.